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ABSTRACT: Arthrogryposis–renal dysfunction–
cholestasis (ARC) syndrome is a rare autosomal
recessive multisystem disorder caused by mutations in
vacuolar protein sorting 33 homologue B (VPS33B) and
VPS33B interacting protein, apical–basolateral polarity
regulator (VIPAR). Cardinal features of ARC include
congenital joint contractures, renal tubular dysfunction,
cholestasis, severe failure to thrive, ichthyosis, and a
defect in platelet alpha-granule biogenesis. Most patients
with ARC do not survive past the first year of life.
We report two patients presenting with a mild ARC
phenotype, now 5.5 and 3.5 years old. Both patients
were compound heterozygotes with the novel VPS33B
donor splice-site mutation c.1225+5G>C in common.
Immunoblotting and complementary DNA analysis
suggest expression of a shorter VPS33B transcript, and
cell-based assays show that c.1225+5G>C VPS33B
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mutant retains some ability to interact with VIPAR (and
thus partial wild-type function). This study provides
the first evidence of genotype–phenotype correlation
in ARC and suggests that VPS33B c.1225+5G>C
mutation predicts a mild ARC phenotype. We have
established an interactive online database for ARC
(https://grenada.lumc.nl/LOVD2/ARC) comprising all
known variants in VPS33B and VIPAR. Also included in
the database are 15 novel pathogenic variants in VPS33B
and five in VIPAR.
HumMutat 33:1656–1664, 2012. C© 2012Wiley Periodicals, Inc.
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Introduction
Arthrogryposis, renal dysfunction, and cholestasis (ARC) syn-
drome (MIM# 208085) is an autosomal recessivemultisystemdisor-
der caused bymutations in vacuolar protein sorting 33homologueB
(VPS33B; MIM# 608552) and VPS33B interacting protein, apical–
basolateral polarity regulator (VIPAR; MIM# 613401) [Cullinane
et al., 2010; Gissen et al., 2004]. Characteristic presentation of ARC
syndrome includes neonatal cholestatic jaundice, renal tubular aci-
dosis, arthrogryposis, and severe failure to thrive. Most patients fail
to survive past the first year of life [Gissen et al., 2006].
VPS33B is a member of the Sec1/Munc18 family proteins, which
directly interact with soluble NSF attachment protein receptors
C© 2012 WILEY PERIODICALS, INC.
(SNAREs) and aid SNARE complex formation, thus facilitating
membrane tethering and fusion [Dulubova et al., 2003; Hata et al.,
1993; Yamaguchi et al., 2002]. VPS33B and VIPAR are homologues
of yeast Vps33 andVps16, respectively. In yeast, these proteins along
with two other class C vps proteins (Vps11 and Vps18) make up
the core of homotypic protein sorting (HOPS) and class C core
vacuole/endosome tethering (CORVET) complexes responsible for
thematuration and control of vesicular trafficking from early to late
endosomes and vacuoles [Peplowska et al., 2007]. In addition to
four class C vps proteins, HOPS and CORVET complexes contain
two other compartment-specific subunits. HOPS contains Vps39
and Vps41, with Vps41 shown to directly interact with Ypt-7-GTP,
a Rab7 orthologue [Brett et al., 2008], whereas CORVET contains
Vps3 and Vps8. Intermediate complexes containing both CORVET-
and HOPS-specific subunits raise the possibility that these com-
plexes may convert “on-the-fly” from one complex to another
[Peplowska et al., 2007]. Study of the subunit organization of HOPS
and CORVET showed that Vps16 is required for Vps33 association
with Vps11 and Vps18 [Rieder and Emr, 1997]; more specifically,
residues 451–595 at the C-terminal domain in yeast Vps16 medi-
ates binding to Vps33 [Pulipparacharuvil et al., 2005]. Vps18 has a
crucial role in the assembly of HOPS and the removal of Vps18 pre-
vents the coimmunoprecipitation of all other subunits with Vps11
[Plemel et al., 2011]. Mammalian equivalents of HOPS have been
studied by several groups [Kim et al., 2001; Nickerson et al., 2009;
Zhu et al., 2009]. In metazoans, there are two homologues of yeast
Vps33, VPS33A and VPS33B. It is probable that VPS33A in meta-
zoans is a part of the HOPS complex [Sriram et al., 2003], but the
conditions in which the VPS33B–VIPAR complex may be involved
in HOPS are unknown [Cullinane et al., 2010; Zlatic et al., 2011].
At present, whether there is a mammalian equivalent of the yeast
CORVET complex is still unclear [Zlatic et al., 2011].
It has been reported that VPS33B forms a complex with VIPAR
and that together they partially colocalize and coimmunoprecipitate
with Rab11a. Rab11a is a small GTPase associated with apical re-
cycling endosomes, thus implicating a role for the VPS33B–VIPAR
complex in the apical recycling pathway [Cullinane et al., 2010].
Furthermore, mislocalization of apical membrane proteins in the
liver and kidneys of ARC patients [Cullinane et al., 2010; Gissen
et al., 2004] and structural and functional abnormalities in the
apical junction complex in mIMCD3 cells with VPS33B and VIPAR
stable knockdown support a role forVPS33B–VIPAR complex in the
maintenance of apical–basolateral polarity [Cullinane et al., 2010].
How the VPS33B–VIPAR complex regulates apical basolateral
polarity has not been delineated. Identification of disease-causing
mutations that modify the structure of wild-type protein can ad-
vance understanding of protein interactions and ultimately of their
roles in intracellular processes. Thus, the aim of our work was to
identify possible links between patient phenotype, genotype, and
the resultant effects of mutations on VPS33B–VIPAR localization
and interaction with HOPS complex. For the first time, we present
two patients with an attenuatedARCphenotype, who both are com-
pound heterozygotes for a novel c.1225+5G>Cmutation inVPS33B.
We summarize all published variants found inVPS33B andVIPAR to
date in a Leiden Open-Source Variation Database (LOVD) for ARC
and report 15 novel mutations in VPS33B and five in VIPAR. Using
a cell-based assay, we investigated the effect of various mutations
that occur in ARC patients on VPS33B–VIPAR complex formation.
In addition, we studied the interaction of the wild-type and mutant
proteins with the HOPS complex protein VPS18 to detect any pos-
sible functional evidence of the interaction of VPS33B–VIPAR and
HOPS complexes.
Materials and Methods
Patients and Controls
Patient clinical data have been obtained in a manner conform-
ing with granting agency ethical guidelines. Informed consent was
obtained from all participating families; research ethics commit-
tees from all participating institutions approved the study. Primary
skin fibroblasts from patients were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum, 2mM L-glutamine, MEM nonessential amino acid solution
(all from Sigma–Aldrich, Poole, United Kingdom). DNA was ex-
tracted from blood or fibroblasts using the DNeasy blood and tissue
kit (Qiagen,Crawley,UnitedKingdom) according tomanufacturer’s
instructions.
VPS33B and VIPAR Sequencing
VPS33B and VIPAR exons and flanking intronic DNA were se-
quenced using polymerase chain reaction (PCR) conditions and
primers previously described [Cullinane et al., 2010; Gissen et al.,
2004]. When exons could not be amplified due to indels, amplifi-
cation of these regions was carried out by long range PCR, primers
were designed within the flanking introns and nested sequencing
was performed. Variants were named according to Human Genome
Variation Society nomenclature guidelines (+1 as the A of the ATG
initiation codon; http://www.HGVS.org) and numbered using the
VPS33B reference sequence (NG_012162.1, NM_018668.3) and the
VIPAR reference sequence (NG_023421.1, NM_022067.3).
ARC–LOVD Database
An online locus-specific ARC database (https://grenada.lumc.nl/
LOVD2/ARC) was compiled using the LOVD software system
[Fokkema et al., 2011]. To establish the database, all relevant
data from Human Gene Mutation Database (www.hgmd.org)
and sequence variants obtained by literature search for “ARC,”
“VPS33B,” and “VIPAR” were collated. The database also
contains variants taken from single-nucleotide polymorphism
database (http://www.ncbi.nlm.nih.gov/projects/dbSNP) [Sherry
et al., 2001]. Anymutations found in patients referred for diagnostic
analysis were also included in the database. Detailed description of
database construction can be found in Supp. Methods.
Protein Structure Predictions of VPS33B and VIPAR
Predictions of protein secondary structure, globularity, and
disorder were performed using GlobPlot (http://globplot.embl.
de/), FoldIndex (http://bip.weizmann.ac.il/fldbin/findex), IUPred
(http://iupred.enzim.hu/), RONN (http://www.oppf.ox.ac.uk/
RONN/), andHHPRED (http://toolkit.tuebingen.mpg.de/hhpred).
Complementary DNA Constructs
Complementary DNA (cDNA) constructs of human full-length
VPS33B and VPS33B–L30P in the pEYFP-C3 vector and VIPAR in
the pCMV-myc vector were used [Cullinane et al., 2010].A VIPAR–
L213P construct was created using the site-directed mutagenesis
kit (Stratagene, Stockport, United Kingdom) according to sup-
plied protocol and was sequence verified. The patient AB VPS33B–
c.1225+5G>C construct required integration of patient cDNA into
the wild-type construct and removal of missing exons.
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Table 1. Novel Pathogenic VPS33B and VIPAR Variants Listed in ARC Database
Database ID Gene Exon DNA Change Protein Change
VPS33B_00221 VPS33B 1 c.67C>T p.(Arg23∗)
VPS33B_00223 VPS33B 1i c.97-2A>C p.(?)a
VPS33B_00231 VPS33B 2i c.178-2A>C p.(?)
VPS33B_00224 VPS33B 2i c.178-1G>C p.(?)
VPS33B_00225 VPS33B 10 c.711del p.(Phe237Leufs∗2)
VPS33B_00226 VPS33B 11i c.853-3C>G p.(?)
VPS33B_00227 VPS33B 13i c.1030+5G>T p.(?)
VPS33B_00230 VPS33B 16i c.1225+5G>C p.(?)
VPS33B_00229 VPS33B 17 c.1261_1262del p.(Gln421Valfs∗8)
VPS33B_00228 VPS33B 20 c.1498G>T p.(Glu500∗)
VPS33B_00232 VPS33B 4 c.240-577_290-156del p.(Leu81Serfs∗5)
VPS33B_00233 VPS33B 3i c.240-1G>C p.(?)
VPS33B_00234 VPS33B 21i c.1657+1G>A p.(?)
VPS33B_00226 VPS33B 11i c.853-3C>G p.(?)
VPS33B_00235 VPS33B 1-23 c.(?_-354)_(∗431+d127_?)del p.(0?)b
VIPAR_00023 VIPAR 9 c.638T>C p.(Leu213Pro)
VIPAR_00021 VIPAR 6 c.463_464del p.(Trp155Glufs∗4)
VIPAR_00022 VIPAR 6 c.484C>T p.(Arg162∗)
VIPAR_00019 VIPAR 13 c.1021T>C p.(Cys341Arg)
VIPAR_00020 VIPAR 11i c.837-1G>T p.(?)
Variants were numbered using the VPS33B RefSeq (NG_012162.1, NM_018668.3) and VIPAR RefSeq (NG_023421.1, NM_022067.3).
Del, deletion; Fs, frameshift; i, intron; ∗, stop;, whole exon deletion.
ap.(?) effect of the variant upon the protein is unknown.
bp.(0?) no protein product is predicted.
Cell Culture and Transfection
All tissue culture reagents were from Sigma–Aldrich unless other-
wise stated. HEK293 cells were maintained in high-glucose (4.5 g/l)
DMEMmedium supplemented with 10% Fetal Bovine Serum (PAA
Laboratories, Somerset, United Kingdom), 2mM L-glutamine, and
MEM nonessential amino acid solution.For experiments, HEK293
cellswere seeded either onplastic plates or glass coverslips, grown for
24 hr and transfected with plasmid DNA using Lipofectamine 2000
according to manufacturer’s protocols (Invitrogen, Paisley, United
Kingdom).
Immunofluorescence Confocal Microscopy
HEK293 cells grown on glass coverslips transfected as above were
allowed 24 hr recovery before fixation (4%paraformaldehyde [PFA]
in PBS) and permeabilization (0.1% Triton X-100 in PBS). Myc-
tagged protein was immunostained with the mouse monoclonal
antibody anti-myc (Clone 9E10) (Sigma, Poole, United Kingdom)
at a 1:400 concentration and anti-mouse ALEXA-568 conjugate
secondary antibody (Invitrogen) at a concentration of 1:400. Nu-
clei were stained with TO-PRO-3 (Invitrogen). Microscopic images
were captured using an inverted Leica TCS SP2 AOBS confocal mi-
croscope with a ×63 oil immersion objective (N/A 1.4) and 3×
optical zoom; the pinhole was set to 1 Airy unit. A series of optical
sections were collected from xy plane and merged into maximum
projection images. Figures were prepared using Photoshop.
Immunoelectron Microscopy
HEK293T cells were fixed by adding freshly prepared 4% PFA or
4% PFA + 0.4% glutaraldehyde (GA) (w/v) (Polysciences, Epple-
heim, Germany) in 0.1 M phosphate buffer (pH 7.4) to an equal
volume of culture medium for 10min, followed by postfixation in
4% PFA or 2% PFA + 0.2% GA (w/v) at 4◦C overnight. Ultrathin
cryosectioning and immunogold labeling were performed as de-
scribed [Slot and Geuze, 2007]. Fixed cells were washed with PBS
containing 0.05 M glycine, scraped gently free, and embedded in
12% gelatin in PBS. The cell pellet was solidified on ice and cut into
small blocks. For cryoprotection, blocks were infiltrated overnight
with 2.3 M sucrose at 4◦C and then mounted on pins and frozen
in liquid nitrogen. Ultrathin cryosections at 70 nm were prepared
on a Leica ultracut UCT ultra cryomicrotome and picked up with
a freshly prepared 1:1 mixture of 2.3M sucrose and 1.8% methyl-
cellulose [Liou et al., 1996]. Ultrathin cryosections were then im-
munogold labeled and examined using a JEOL TEM 1010 electron
microscope at 80 kV.
Antibodies used included biotinylated polyclonal goat anti-GFP
(Rockland, Gilbertsville, PA) used to localize YFP-tagged proteins;
polyclonal rabbit anti-biotin (Rockland) was used as a bridging
antibody between the biotinylated anti-GFP antibody and the pro-
tein A-gold, monoclonal anti-myc (9E10) (Santa Cruz Biotechnol-
ogy, Heidelberg, Germany), monoclonal anti-Tf receptor (Zymed,
Barcelona, Spain), and a polyclonal rabbit anti-mouse antibody
(DAKO, Glostrup, Denmark) to bridge mouse monoclonal anti-
body to protein A-gold.
Results
Identification of Patients with an Attenuated ARC
Phenotype
Patients with the suspected diagnosis of ARC were referred to
our group for clinical and molecular diagnosis. Twenty novel mu-
tations in VPS33B and VIPAR were identified in patients with the
classical features of ARC (see Table 1). Patient AB was referred for
mutation screening at 2.5 years with what appeared to be an attenu-
ated phenotype of ARC. AB is of nonconsanguineous Peruvian and
Puerto Rican descent. His clinical features included failure to thrive,
developmental delay with sensorineural hearing loss, renal loss of
protein and amino acids, bilateral talipes with osteopenia, and mild
cholestasis. Magnetic resonance imaging (MRI) showed dysmor-
phic ventricles with coaptation of the occipital horns and irregular
lateral–ventricular marginal contours. Mild confluent hyperintense
T2 signal in the periventricular whitematter suggested early in utero
ischemic injury. Troublesome pruritus and ichthyosis were associ-
ated with increased serum concentrations of bile acids and did not
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Figure 1. Patients with attenuated ARC syndrome. A–D: Patient AB. Aged (A) 3 years and (B) 5 years. Hyperkeratosis and lichenification of palm
of right hand (C) and sole of left foot (D). E–I: Patient CD. Facies aged 3 (E); in plaster after corrective hip surgery (F). Hyperkeratosis, dorsum of
right foot (G). Radiographs of right foot showing vertical talus (H) and of pelvis showing hip dislocation (I).
respond to conventional therapy. Clinical management with sup-
plemental feeds via gastric tube achieved steady growth along the
0.3rd percentile for his weight and height. Pruritus responded to
cutaneous biliary diversion performed at age 3 years (Fig. 1A–D).
Sequencing of VPS33B revealed that Patient AB is a compound
heterozygote for mutations in VPS33B. One allele harbors the dele-
tion c.240–577_290-156del; absence of exon 4 from the cDNA re-
sults in a frameshift and premature stop codon, p.(Leu81Serfs∗5)
(see Supp. Fig. S1). The other allele harbors the donor splice-site
mutation c.1225+5G>C.
At the age of 5.5 years, AB attends kindergarten and a special
school for children with hearing impairment. He is making slow
progress in his development, such as learning to say two-syllable
words. AB has difficulties with using sign language due to severe
hyperkeratosis and lichenification of the skin of his hands. He can
walk unaided. He likes to play with other children particularly bas-
ketball, when he likes to dribble the ball and to shoot baskets. He
can ride a bicycle with training wheels. Although thick, calloused
hand skin (Fig. 1C) interferes with fine motor tasks, this problem
seems to be responding to dermatological management.
AB continues to have osteopenia with shortening of the proximal
fibula, generalized aminoaciduria and nephrotic range proteinuria,
and recurrent episodes of epistaxis associated with the absence of
platelet alpha-granules.
Patient CD, with the features of possible ARC, was referred for a
clinical assessment aged 12months. Her parents are of Puerto Rican
and Jualisco Mexican origin. She was found to have arthrogryposis
and failure to thrive at age of 2 weeks. Investigations identified renal
tubular dysfunction, mild cholestasis, hyperpigmented lichenified
skin, bilateral hip dislocations, decreased muscle bulk, and sen-
sorineural hearing loss (Fig. 1E–I). She was not jaundiced but had
hypercholanemia. MRI at 14 months showed a thin corpus callo-
sum and diffuse paucity of white matter. However, she continued
to progress in development with appropriate socialization. Speech
improved after a hearing aid was fitted. Pruritus improved with
rifampicin, phenobarbitone, and ursodeoxycholic acid treatment.
CD continues to fail to thrive despite supplementary feeds. At age 3
years, sheunderwent corrective surgery for hipdysplasia; she is start-
ing to walk. Additional clinical problems include abnormal dental
composition with weak enamel and easily chipped teeth (Fig. 1E).
Sequencing by Prevention Genetics found the patient to be a
compoundheterozygote formutation inVPS33B.One allele harbors
the mutation c.1261_1262delCA, predicted to result in a frameshift
and premature protein termination (p.Gln421Valfs∗8). The other
harbors the mutation c.1225+5G>C, the splice donor site mutation
identified in patient AB.
Although the mutations present were predicted to yield a severe
phenotype, both AB and CD had an attenuated form of ARC. This
finding merited further investigation. Immunoblotting of protein
obtained from AB’s fibroblasts indicated the presence of VPS33B
protein product shorter than control (Supp. Fig. S2C). When 3′-
RACEwas used to amplify theVPS33B transcript of unknown com-
position resulting from the splice-site mutation, 114 bp of intron
16 were found integrated into the VPS33B transcript before ter-
mination with a polyA tail (Supp Fig. S2B). The predicted protein
composition therefore includes 12 additional amino acid residues,
encoded by this intronic sequence, before a stop codon. Exons 17–
23 are absent from the cDNA, thus resulting in a predicted pro-
tein length of 420 aa in comparison to the wild-type 617aa (Supp.
Fig. S2D).
Mutations in VPS33B and VIPAR and ARC–LOVD Database
We have compiled an online locus-specific ARC database
(https://grenada.lumc.nl/LOVD2/ARC), using the LOVD software
system [Fokkema et al., 2011] that lists all identified variants in
VPS33B and VIPAR. The database includes 15 previously unpub-
lished variants in VPS33B and five in VIPAR that have been classed
as “pathogenic” (Table 1).
As of January 2012, the ARC database contained 235 unique
variants inVPS33B and23 inVIPAR. Forty-sevenvariants inVPS33B
have been classed as “pathogenic” or “probably pathogenic” due to
their predicted effect on the protein and the clinical presentation of
the patients in whom they were found (Fig. 2). Most of these are
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substitutions (n = 32; 20 splice site, 10 nonsense, and twomissense).
There are also deletions (n = 9; including 1 whole gene deletion),
duplications (n = 2), insertions (n = 1), and indels (n = 1), all ofwhich
are predicted to result in frameshift and premature termination of
transcription.
There are nine recurrent variants in VPS33B, of which three are
more prevalent; a splice-site mutation, c.403+2T>A (reported in
11 individual patients, all of Korean origin), a nonsense mutation,
c.1312C>T (reported in nine patients; eight of Pakistani origin,
and one Arabic), and a nonsense mutation c.1519C>T (reported
in seven patients; three Portuguese, one Korean, one Hispanic, two
unknown ethnicity) (references within the database). Molecular
diagnosis in research and service laboratories in addition has iden-
tified c.1312C>T and c.1519C>T mutations in additional patients
with ARC from relevant ethnic groups (Paul Gissen, personal com-
munication).
Of 11 “pathogenic” variants in VIPAR (Fig. 2), most are substi-
tutions (n = 8; five nonsense and two missense), with two deletions
(resulting in frameshift) and one splice-site mutation. Two variants
recur: the nonsense mutation, c.658C>T (reported in two patients;
ethnic origins Italian and Turkish) and the nonsense mutation,
c.808C>T (reported in two patients; ethnic origins Pakistani and
Arab–Israeli).
The distribution of variants is relatively uniform within VPS33B;
we identified no obviousmutational hotspots (Fig. 2). Protein struc-
ture predictions for VPS33B and VIPAR suggest that both proteins
contain globular regions with well-defined secondary structure el-
ements. VPS33B contains a Sec1 domain (amino acids 31–611)
spanning almost the entire protein. Structure–prediction software
has consistently identified a large disordered protein segment at
the N-terminus of VIPAR. At present, with the exception of a sin-
gle pathogenic mutation in the start codon, the N-terminal part
of VIPAR is devoid of mutations. This might suggest that this re-
gion of VIPAR is dispensable for VPS33B–VIPAR interaction. Pro-
tein secondary structure, globularity, and disorder were predicted
using GlobPlot (http://globplot.embl.de/), FoldIndex (http://bip.
weizmann.ac.il/fldbin/findex), IUPred (http://iupred.enzim.hu/),
RONN (http://www.oppf.ox.ac.uk/RONN/), andHHPRED (http://
toolkit.tuebingen.mpg.de/hhpred).
Identification of a Correlation between Genotype and
Cellular Phenotype
Nonsense and frameshift mutations in VPS33B and VIPAR are
associated with severe clinical phenotype and likely result in absent
protein product due to premature termination of transcription and
nonsense-mediateddecay [Cullinane et al., 2009]. Themissensemu-
tations identified so far likely result in an expressed protein product,
however are also associated with severe clinical phenotype. Finally, a
novel splice-site mutation in VPS33B reported here, c.1225+5G>C,
resulting in a truncated protein product, is associated with an at-
tenuated ARC phenotype.
Mutations predicted to result in an expressed protein from pa-
tients with phenotypes assessed as severe (VPS33B p.Leu30Pro and
VIPAR p.Leu213Pro) and moderate (VPS33B c.1225+5G>C) were
selected from the database for modeling to gain further insight into
disease pathogenesis and VPS33B and VIPAR function (Supp. Ta-
ble S1).
Overexpression of wild-type VPS33B and VIPARwithin HEK293
cells has found that these two proteins strongly colocalize to defined
spots, and that these partially colocalize with RAB11A, a marker for
recycling endosomes [Cullinane et al., 2010].
We used transfections of epitope-tagged constructs to investigate
whether patient mutations in VPS33B or VIPAR disrupt the in-
teraction between these proteins when overexpressed in HEK293
cells using colocalization studies. Although wild-type VPS33B and
VIPAR colocalized (Fig. 3A), co-overexpression of VPS33B and
VIPAR(L213P) mutant did not result in colocalization; a cytoplas-
mic distribution for both proteins was observed (Fig. 3B). Similarly,
co-overexpression of VPS33B(L30P) mutant with VIPAR (Fig. 3C)
also resulted in cytoplasmic distribution for both proteins. The
severe clinical phenotype associated with these mutations confirms
the importance of VPS33B–VIPAR complex formation for the func-
tion of these proteins. Finally, when VPS33B(c.1225+5G>C)mutant
(known to be associated with an attenuated clinical phenotype, see
above) was co-overexpressed with wild-type VIPAR (Fig. 3D), spe-
cific fluorescent spots containing both proteins were observed. In
addition, aggregates containing only VPS33B could be seen. Thus, it
appears that the c.1225+5G>CVPS33Bmutant retains partial ability
to interact with VIPAR.
To investigate the sites of colocalization of VPS33B and VIPAR
in ultrastructural detail, we performed cryo-immunogold electron
microscopy (EM) of HEK293 cells overexpressing different com-
binations of constructs. This showed that the wild-type proteins
colocalized on endosome-associated tubular–vesicular membranes
also positive for transferrin receptor (Fig. 4A and B). The mor-
phological and molecular characteristics of these membranes, in-
cluding the presence of Rab11A as seen by immunofluorescence,
identifies them as recycling endosomes [Sachse et al, 2002]. When
VPS33B (c.1225+5G>C) mutant was cotransfected with VIPAR, the
two proteins colocalized mainly in electrondense cytoplasmic clus-
ters that contained no membranes (Fig. 4C). Interestingly how-
ever, some staining for VPS33B(c.1225+5G>C) could be detected
on vesicles found at the rims of these cytoplasmic aggregates. Thus,
the VPS33B(c.1225+5G>C) mutation seems to affect the ability of
the complexes to colocalize properly on tubular–vesicular recycling
membranes, which is likely to abrogate at least partially its cellular
functioning.
To identify whether VPS33B and/or VIPARmay interact with the
mammalian HOPS complex, we studied their colocalization with
human VPS18 protein, which has a central role in HOPS subunit
interactions [Ostrowicz et al., 2010; Plemel et al., 2011].
When VPS18 was co-overexpressed with VPS33B, the two pro-
teins did not colocalize: VPS33Bwas cytoplasmic andVPS18 formed
small spots (Fig. 5A). When VPS18 was co-overexpressed with
VIPAR, there was colocalization in large fluorescent spots (Fig. 5B).
However, by immuno-EM these spots were identified as cytoplasmic
aggregates, without any membranes associated (Fig. 4D).
Interestingly, when all three constructs were cotransfected into
HEK293 cells (Fig. 5C), VIPAR colocalized and formed clusters
with VPS33B, whereas VPS18 was cytoplasmic. These interac-
tions were confirmed by coimmunoprecipitation experiments: HA-
VIPAR could pull down members of the HOPS complex, espe-
cially VPS18 where a strong interaction was seen (Supp. Fig. S3A).
However, when this experiment was repeated in the presence
of overexpressed YFP-VPS33B, this strong interaction diminished
considerably, confirming the immunofluorescence findings (Supp.
Fig. S3B).
Discussion
ARC is a severe multisystem childhood disorder caused by muta-
tions in either VPS33B or VIPAR. Here, we report 20 novel muta-
tions in VPS33B or VIPAR. Also, for the first time we describe two
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Figure 3. VPS33B and VIPAR interaction. Confocal fluorescence photomicrographs of HEK293 cells cotransfected with wild-type and mutant
constructs of YFP-tagged VPS33B and Myc-tagged VIPAR. Wild-type YFP-VPS33B and Myc-VIPAR colocalized (A). However, constructs modeled
on severe phenotype mutant proteins (B) Myc-VIPAR(L213P) and (C) YFP-VPS33B(L30P) resulted in a disruption of VPS33B–VIPAR interaction. D:
Transfection for YFP-VPS33B(c.1225G>C), modeling an attenuated phenotype, resulted in partial colocalization. Myc-VIPAR was immunostained
with mouse monoclonal antibody anti-myc (Sigma) at a 1:400 concentration and anti-mouse ALEXA-568 conjugate secondary antibody (Invitrogen)
at a concentration of 1:400. Nuclei are stained with TO-PRO-3. Scale bars, 10μm.
Figure 4. Ultrastructual localizations of VPS33B, VPS33B(c.1225G>C), VIPAR, and VPS18 constructs. Transmission electron micrographs of
ultrathin cryosections of HEK293 cells. A, B: Cells cotransfected with YFP-tagged VPS33B and Myc-tagged VIPAR were immunogold stained with
anti-GFP/YFP (15 nanometer gold) and anti-Myc (10 nanometer gold) (A), or anti-GFP/YFP (15 nanometer gold) and anti-TfR (10 nanometer gold) (B).
Colocalization was observed on endosome (E)-associated tubular–vesicular membranes typical of recycling endosomes, which was confirmed by
the presence of TfR (arrows in B). (C) Cells co-overexpressing YFP-VPS33B(c.1225G>C) andMyc-VIPARwere immunogold labeled for anti-GFP/YFP
(15 nanometer gold) andMyc (10 nanometer gold). The two proteins colocalized in cytosolic aggregates with partial staining of VPS33B(c.1225G>C)
on nearby vesicles (arrows). D: Cells co-overexpressing YFP-tagged VIPAR (labeled with anti-GFP; 10 nanometer gold) and Myc-tagged VPS18
(labeled with anti-Myc, 15 nanometer gold) showed colocalization in cytosolic aggregates. E, endosome; N, nucleus; PM, plasma membrane. Scale
bars, 200 nm.
1662 HUMANMUTATION, Vol. 33, No. 12, 1656–1664, 2012
Figure 5. VPS33B and VIPAR interaction with VPS18. Confocal fluorescence photomicrographs of HEK293 cells cotransfected with (A) YFP-
VPS33B and Myc-VPS18 found these proteins do not colocalize. However, (B) mCherry–VIPAR and Myc-VPS18 do colocalize in clusters in the
absence of YFP-VPS33B. If all three proteins were cotransfected, then YFP-VPS33B and mCherry-VIPAR formed clusters andMyc-VPS18 assumed
independent cytoplasmic distribution (C). Myc-VPS18 was immunostained with mouse monoclonal antibody anti-myc (Sigma) and anti-mouse
ALEXA-568 conjugate secondary antibody (Invitrogen), both at a concentration of 1:400. Scale bar, 10μm.
patients with an attenuated ARC phenotype. They have in com-
mon the c.1225+5G>C splice-site mutation in VPS33B, which
we have shown to result in a truncated protein that may retain
some wild-type function as a result of forming VPS33B–VIPAR
complex-containing clusters. In contrast, the mutated proteins
VPS33B(L30P) and VIPAR(L213P), which are associated with a
severe ARC phenotype, did not form clusters with their respec-
tive wild-type partners. The mutation L30P, modeled using bioin-
formatics analysis [Gissen et al., 2005], is predicted to disrupt an
alpha-helix. Predicted secondary structure of wild-type VIPAR in-
cludes an extended disordered region at the N-terminus (residues
1–150), followed by a 100% alpha-helical domain that extends to
the C-terminus (residues 105–491). According to these predictions,
residues 209–218 are part of a buried alpha-helical segment. A
Leu213Pro substitution in VIPAR is predicted to result in the dis-
ruption of this alpha-helix in the core of a folded region of VIPAR
structure, and might affect the overall folding of the protein and its
interactions with VPS33B and/or other potential binding partners.
A splice site c.1225+5G>C mutation in VPS33B generates a trun-
cated formof VPS33B (residues 1–420) that still partially colocalizes
with VIPAR (Fig. 3D). From this evidence and also the EM exper-
iments, we can affirm that truncation of the C-terminal region of
VPS33B, as seen with the c.1225+5G>C splice mutation, may alter
the overall interaction between VPS33B and VIPAR and the local-
ization of the complex. However, the attenuated clinical phenotype
and the presence in cell culture of VPS33B- and VIPAR-containing
clusters suggest that some of the function of the VPS33B–VIPAR
complex may be retained. Point mutations in the same C-terminal
region might alter folding throughout VPS33B secondary structure
and completely abrogate normal interaction with VIPAR. The find-
ing that clusters containing VPS33B(c1225+5G>C) and VIPAR are
mainly cytoplasmic suggests that the expected interaction of SM
protein VPS33B with transmembrane SNAREs might be important
for the proper localization and function of the complex. In addi-
tion, interaction with SNARE proteins might be possible only after
VIPAR binding to VPS33B, since overexpression of VPS33B alone
is not sufficient to localize VPS33B on recycling endosomes.
We also studied VPS33B and VIPAR interaction with the core
HOPS complex protein VPS18. As our results suggest that VIPAR
may interact with VPS18 only in the absence of VPS33B, the
VPS33B–VIPAR complex is unlikely to be involved in HOPS in-
teraction. However, VIPAR may interact with VPS18 in cells with
mutant VPS33B, implying that this interaction might be involved
in ARC pathogenesis.
The HOPS complex is involved in biogenesis of late endosomes
and phagosomes and in cargo delivery to the vacuole/lysosome,
thus resulting in protein degradation in both yeast and multicellu-
lar organisms [Lindmo et al., 2006; Nickerson et al., 2009; Pulippa-
racharuvil et al., 2005; Rieder andEmr, 1997; Sevrioukov et al., 1999;
Sriram et al., 2003]. We have shown that in cell lines with VPS33B
or VIPAR knockdown, degradation of some apical membrane pro-
teins is increased [Cullinane et al., 2010]. Thus, it is conceivable that
deficiency of VPS33B or VIPAR in ARC results in rerouting of apical
membrane proteins into lysosomes.
Our work broadens the clinical phenotype of VPS33B andVIPAR
deficiencies and provides increased understanding of the effect of
protein alteration on intracellular trafficking. We have developed
the ARC–LOVD database to provide a resource for researchers and
clinicians, allowing easy access to a central log of updated infor-
mation, and to provide the opportunity to share data. We hope
that as data are added, opportunities for epidemiological investiga-
tions and meta-analysis will increase. The identification of a range
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of phenotypic severity in ARC underlines the importance of such a
database to help accurately counsel patient families on prognosis. In
addition, advances in knowledge of ARC pathogenesis and clinical
course may lead to novel therapies and improved management of
patients with ARC.
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